| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 33 | 2016 | 129 | 6.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 42 | 2017 | 456 | 5.790 |
Why?
|
| Deoxycytidine | 28 | 2014 | 63 | 3.200 |
Why?
|
| Camptothecin | 19 | 2014 | 48 | 2.670 |
Why?
|
| Antineoplastic Agents | 18 | 2016 | 599 | 1.910 |
Why?
|
| Colorectal Neoplasms | 13 | 2015 | 222 | 1.880 |
Why?
|
| Lung Neoplasms | 20 | 2015 | 428 | 1.600 |
Why?
|
| Adenocarcinoma | 12 | 2015 | 300 | 1.550 |
Why?
|
| Neoplasms | 12 | 2016 | 761 | 1.250 |
Why?
|
| Taxoids | 11 | 2017 | 55 | 1.180 |
Why?
|
| Fluorouracil | 12 | 2014 | 82 | 1.150 |
Why?
|
| Antimetabolites, Antineoplastic | 8 | 2010 | 49 | 1.110 |
Why?
|
| Organoplatinum Compounds | 8 | 2014 | 46 | 1.010 |
Why?
|
| Carcinoma, Small Cell | 8 | 2012 | 22 | 1.000 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 10 | 2006 | 112 | 1.000 |
Why?
|
| Middle Aged | 57 | 2017 | 12125 | 0.880 |
Why?
|
| Antibodies, Monoclonal | 10 | 2013 | 240 | 0.850 |
Why?
|
| Aged | 52 | 2017 | 10538 | 0.840 |
Why?
|
| Humans | 87 | 2017 | 32798 | 0.840 |
Why?
|
| Paclitaxel | 5 | 2013 | 67 | 0.800 |
Why?
|
| Adult | 44 | 2017 | 9560 | 0.750 |
Why?
|
| Treatment Outcome | 27 | 2017 | 3438 | 0.700 |
Why?
|
| Male | 56 | 2017 | 19641 | 0.680 |
Why?
|
| Female | 56 | 2017 | 20261 | 0.650 |
Why?
|
| Salvage Therapy | 4 | 2011 | 134 | 0.650 |
Why?
|
| Neoadjuvant Therapy | 7 | 2012 | 66 | 0.650 |
Why?
|
| Colonic Neoplasms | 3 | 2010 | 74 | 0.630 |
Why?
|
| Neoplasm Metastasis | 7 | 2014 | 220 | 0.630 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2015 | 205 | 0.620 |
Why?
|
| Disease-Free Survival | 11 | 2017 | 326 | 0.590 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2005 | 35 | 0.590 |
Why?
|
| Gastrointestinal Stromal Tumors | 5 | 2010 | 12 | 0.590 |
Why?
|
| Drug Administration Schedule | 11 | 2016 | 271 | 0.570 |
Why?
|
| Survival Analysis | 11 | 2014 | 486 | 0.550 |
Why?
|
| Cancer Vaccines | 2 | 2014 | 24 | 0.530 |
Why?
|
| Indoles | 4 | 2016 | 56 | 0.530 |
Why?
|
| Leucovorin | 3 | 2012 | 23 | 0.530 |
Why?
|
| Aged, 80 and over | 24 | 2017 | 4032 | 0.520 |
Why?
|
| Pyrroles | 4 | 2016 | 52 | 0.520 |
Why?
|
| Maximum Tolerated Dose | 10 | 2014 | 60 | 0.510 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2016 | 18 | 0.510 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2017 | 384 | 0.510 |
Why?
|
| Carcinoma | 3 | 2012 | 92 | 0.500 |
Why?
|
| Neoplasm Staging | 11 | 2014 | 470 | 0.490 |
Why?
|
| Palliative Care | 2 | 2010 | 51 | 0.490 |
Why?
|
| Endosonography | 4 | 2011 | 53 | 0.470 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2012 | 84 | 0.470 |
Why?
|
| Topotecan | 4 | 2009 | 17 | 0.460 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2016 | 38 | 0.450 |
Why?
|
| Gastrins | 1 | 2014 | 4 | 0.440 |
Why?
|
| Survival Rate | 15 | 2012 | 894 | 0.410 |
Why?
|
| Esophageal Neoplasms | 3 | 2011 | 39 | 0.410 |
Why?
|
| Albumins | 1 | 2013 | 44 | 0.400 |
Why?
|
| Stomach Neoplasms | 3 | 2014 | 113 | 0.390 |
Why?
|
| Cell Cycle | 1 | 2012 | 74 | 0.380 |
Why?
|
| Antimitotic Agents | 1 | 2012 | 2 | 0.370 |
Why?
|
| Rectal Neoplasms | 2 | 2009 | 21 | 0.370 |
Why?
|
| Oligopeptides | 1 | 2012 | 43 | 0.370 |
Why?
|
| Clinical Trials as Topic | 6 | 2008 | 307 | 0.360 |
Why?
|
| Piperidines | 2 | 2012 | 120 | 0.360 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2011 | 52 | 0.350 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 157 | 0.340 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2017 | 10 | 0.340 |
Why?
|
| Cytoskeletal Proteins | 1 | 2010 | 14 | 0.340 |
Why?
|
| Infusions, Intravenous | 5 | 2014 | 97 | 0.330 |
Why?
|
| Drug Therapy | 1 | 2010 | 16 | 0.320 |
Why?
|
| Biopsy, Needle | 2 | 2008 | 90 | 0.310 |
Why?
|
| DNA Methylation | 1 | 2010 | 144 | 0.310 |
Why?
|
| Prognosis | 9 | 2015 | 1544 | 0.300 |
Why?
|
| Etoposide | 3 | 2007 | 36 | 0.300 |
Why?
|
| CA-19-9 Antigen | 2 | 2013 | 7 | 0.290 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2008 | 21 | 0.280 |
Why?
|
| Emphysematous Cholecystitis | 1 | 2007 | 1 | 0.270 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 105 | 0.260 |
Why?
|
| Ultrasonography, Interventional | 2 | 2011 | 52 | 0.260 |
Why?
|
| Quinazolines | 4 | 2008 | 38 | 0.260 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2007 | 13 | 0.260 |
Why?
|
| Mediastinal Neoplasms | 1 | 2006 | 13 | 0.250 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2012 | 107 | 0.250 |
Why?
|
| Ablation Techniques | 2 | 2016 | 24 | 0.240 |
Why?
|
| Lymph Nodes | 1 | 2006 | 114 | 0.230 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2015 | 532 | 0.230 |
Why?
|
| Electroporation | 2 | 2016 | 14 | 0.230 |
Why?
|
| Combined Modality Therapy | 7 | 2010 | 563 | 0.220 |
Why?
|
| Disease Progression | 5 | 2010 | 594 | 0.220 |
Why?
|
| Retrospective Studies | 11 | 2016 | 3701 | 0.220 |
Why?
|
| Coronary Vasospasm | 1 | 2004 | 4 | 0.210 |
Why?
|
| Diarrhea | 3 | 2014 | 58 | 0.210 |
Why?
|
| Follow-Up Studies | 7 | 2014 | 2284 | 0.210 |
Why?
|
| Hospitals, General | 1 | 2013 | 4 | 0.210 |
Why?
|
| Cancer Care Facilities | 1 | 2013 | 11 | 0.210 |
Why?
|
| Liver Neoplasms | 3 | 2014 | 154 | 0.200 |
Why?
|
| Drug Synergism | 3 | 2014 | 64 | 0.200 |
Why?
|
| Carboplatin | 5 | 2007 | 51 | 0.190 |
Why?
|
| Genetic Markers | 1 | 2002 | 125 | 0.190 |
Why?
|
| Vomiting | 2 | 2014 | 22 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2016 | 947 | 0.150 |
Why?
|
| Nausea | 2 | 2014 | 52 | 0.150 |
Why?
|
| Pancreatic Diseases | 2 | 2010 | 19 | 0.150 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2010 | 38 | 0.150 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2011 | 32 | 0.150 |
Why?
|
| European Continental Ancestry Group | 2 | 2014 | 1163 | 0.150 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2002 | 30 | 0.150 |
Why?
|
| Piperazines | 2 | 2010 | 52 | 0.140 |
Why?
|
| Pyrimidines | 2 | 2010 | 62 | 0.140 |
Why?
|
| Pyridines | 2 | 2008 | 74 | 0.140 |
Why?
|
| Endothelins | 1 | 2017 | 4 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 647 | 0.130 |
Why?
|
| Radiography, Interventional | 1 | 2016 | 32 | 0.130 |
Why?
|
| Young Adult | 4 | 2014 | 2730 | 0.120 |
Why?
|
| African Americans | 2 | 2014 | 1424 | 0.120 |
Why?
|
| Epothilones | 1 | 2016 | 3 | 0.120 |
Why?
|
| Tubulin Modulators | 1 | 2016 | 9 | 0.120 |
Why?
|
| Pancreatectomy | 2 | 2012 | 25 | 0.120 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2006 | 14 | 0.120 |
Why?
|
| Thrombocytopenia | 1 | 2015 | 28 | 0.120 |
Why?
|
| Splenic Artery | 1 | 2015 | 9 | 0.120 |
Why?
|
| Breast Neoplasms | 3 | 2012 | 754 | 0.110 |
Why?
|
| Neutropenia | 1 | 2014 | 27 | 0.110 |
Why?
|
| Sensitivity and Specificity | 4 | 2011 | 576 | 0.110 |
Why?
|
| Embolization, Therapeutic | 1 | 2015 | 82 | 0.110 |
Why?
|
| Electrochemotherapy | 1 | 2014 | 3 | 0.110 |
Why?
|
| Injections, Intramuscular | 1 | 2014 | 42 | 0.110 |
Why?
|
| Time Factors | 4 | 2016 | 2183 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 2017 | 403 | 0.110 |
Why?
|
| Perception | 1 | 2014 | 104 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 497 | 0.100 |
Why?
|
| Pancreas | 2 | 2011 | 103 | 0.100 |
Why?
|
| Quality of Life | 3 | 2004 | 961 | 0.100 |
Why?
|
| Receptor, erbB-2 | 1 | 2014 | 65 | 0.100 |
Why?
|
| Arsenic | 1 | 2013 | 3 | 0.100 |
Why?
|
| Hematologic Diseases | 2 | 2004 | 23 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2010 | 24 | 0.100 |
Why?
|
| Attitude to Health | 1 | 2014 | 163 | 0.100 |
Why?
|
| Trisaccharides | 1 | 2012 | 1 | 0.100 |
Why?
|
| Deoxyglucose | 1 | 2012 | 16 | 0.100 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2012 | 8 | 0.100 |
Why?
|
| Immunotherapy, Active | 1 | 2012 | 6 | 0.100 |
Why?
|
| Prospective Studies | 7 | 2014 | 2327 | 0.100 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2012 | 22 | 0.100 |
Why?
|
| Drug Design | 1 | 2012 | 45 | 0.100 |
Why?
|
| Benzamides | 2 | 2010 | 54 | 0.100 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2004 | 11 | 0.100 |
Why?
|
| Environmental Exposure | 1 | 2013 | 89 | 0.090 |
Why?
|
| Adolescent | 4 | 2014 | 3638 | 0.090 |
Why?
|
| Algorithms | 2 | 2012 | 511 | 0.090 |
Why?
|
| Catheter Ablation | 1 | 2012 | 114 | 0.090 |
Why?
|
| Triazines | 1 | 2011 | 3 | 0.090 |
Why?
|
| Cell Line, Tumor | 2 | 2010 | 726 | 0.090 |
Why?
|
| Boronic Acids | 2 | 2008 | 8 | 0.090 |
Why?
|
| Alanine | 1 | 2011 | 27 | 0.090 |
Why?
|
| Pyrazines | 2 | 2008 | 12 | 0.090 |
Why?
|
| Celiac Plexus | 1 | 2011 | 3 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2010 | 526 | 0.090 |
Why?
|
| Family | 1 | 2011 | 115 | 0.090 |
Why?
|
| Metalloproteases | 1 | 2010 | 3 | 0.090 |
Why?
|
| Diagnostic Imaging | 2 | 2008 | 97 | 0.080 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2010 | 16 | 0.080 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2010 | 5 | 0.080 |
Why?
|
| Abdominal Pain | 1 | 2011 | 43 | 0.080 |
Why?
|
| Azacitidine | 1 | 2010 | 28 | 0.080 |
Why?
|
| Mutation | 2 | 2010 | 493 | 0.080 |
Why?
|
| Gene Silencing | 1 | 2010 | 45 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 71 | 0.080 |
Why?
|
| Transfection | 1 | 2010 | 184 | 0.080 |
Why?
|
| Caregivers | 1 | 2011 | 121 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 117 | 0.080 |
Why?
|
| Biliary Tract Diseases | 1 | 2010 | 12 | 0.080 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2010 | 28 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 208 | 0.080 |
Why?
|
| Cisplatin | 3 | 2011 | 81 | 0.080 |
Why?
|
| Proteins | 1 | 2010 | 142 | 0.080 |
Why?
|
| Radiation Tolerance | 1 | 2009 | 24 | 0.080 |
Why?
|
| Models, Genetic | 1 | 2009 | 94 | 0.080 |
Why?
|
| Lymphatic Metastasis | 2 | 2007 | 169 | 0.080 |
Why?
|
| Gene Expression | 1 | 2009 | 334 | 0.070 |
Why?
|
| Benzenesulfonates | 1 | 2008 | 3 | 0.070 |
Why?
|
| Depression | 1 | 2011 | 448 | 0.070 |
Why?
|
| Phenylurea Compounds | 1 | 2008 | 10 | 0.070 |
Why?
|
| Niacinamide | 1 | 2008 | 8 | 0.070 |
Why?
|
| Endoscopy | 1 | 2008 | 56 | 0.070 |
Why?
|
| DNA Topoisomerases, Type I | 2 | 2006 | 9 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2009 | 133 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2008 | 123 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2007 | 189 | 0.070 |
Why?
|
| Cholecystostomy | 1 | 2007 | 1 | 0.070 |
Why?
|
| Hyperbilirubinemia | 1 | 2007 | 2 | 0.070 |
Why?
|
| Leukocytosis | 1 | 2007 | 7 | 0.070 |
Why?
|
| Phosphorylcholine | 1 | 2007 | 5 | 0.070 |
Why?
|
| Probability | 1 | 2007 | 157 | 0.060 |
Why?
|
| Radiography | 2 | 2012 | 386 | 0.060 |
Why?
|
| Risk Factors | 2 | 2014 | 3974 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 764 | 0.060 |
Why?
|
| Acute Disease | 1 | 2007 | 259 | 0.060 |
Why?
|
| Sarcoma | 1 | 2007 | 71 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2007 | 308 | 0.060 |
Why?
|
| Equipment Design | 1 | 2006 | 179 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2006 | 180 | 0.060 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2004 | 2 | 0.060 |
Why?
|
| Thalidomide | 1 | 2005 | 30 | 0.060 |
Why?
|
| Quinolones | 1 | 2004 | 7 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2010 | 622 | 0.060 |
Why?
|
| Electrocardiography | 2 | 2012 | 636 | 0.060 |
Why?
|
| Enterocolitis, Neutropenic | 1 | 2004 | 1 | 0.050 |
Why?
|
| Aniline Compounds | 1 | 2014 | 18 | 0.050 |
Why?
|
| Patient Selection | 2 | 2007 | 281 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 32 | 0.050 |
Why?
|
| Imidazoles | 1 | 2004 | 92 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 332 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2008 | 686 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2004 | 59 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2014 | 67 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 163 | 0.050 |
Why?
|
| Hospitals, Voluntary | 1 | 2013 | 2 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 21 | 0.050 |
Why?
|
| Blood-Brain Barrier | 1 | 2003 | 50 | 0.050 |
Why?
|
| SEER Program | 3 | 2007 | 33 | 0.050 |
Why?
|
| Poverty | 1 | 2013 | 116 | 0.050 |
Why?
|
| Survival | 1 | 2002 | 12 | 0.050 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2002 | 6 | 0.050 |
Why?
|
| Safety | 1 | 2002 | 77 | 0.050 |
Why?
|
| Age Distribution | 1 | 2002 | 201 | 0.040 |
Why?
|
| Stress, Psychological | 2 | 2014 | 226 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2001 | 22 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2001 | 23 | 0.040 |
Why?
|
| Hematologic Neoplasms | 1 | 2001 | 34 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 779 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2000 | 111 | 0.040 |
Why?
|
| Florida | 2 | 2013 | 38 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2010 | 92 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 60 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 767 | 0.030 |
Why?
|
| Incidence | 2 | 2013 | 1238 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 80 | 0.030 |
Why?
|
| Registries | 2 | 2007 | 315 | 0.030 |
Why?
|
| Georgia | 1 | 2014 | 14 | 0.030 |
Why?
|
| Family Relations | 1 | 2014 | 18 | 0.030 |
Why?
|
| Epirubicin | 1 | 2014 | 1 | 0.030 |
Why?
|
| Water Supply | 1 | 2013 | 10 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 167 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 39 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 126 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 7 | 0.020 |
Why?
|
| Placebos | 1 | 2012 | 63 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2012 | 21 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 145 | 0.020 |
Why?
|
| Esophagogastric Junction | 1 | 2011 | 8 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2011 | 11 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2011 | 13 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2011 | 16 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2011 | 15 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2011 | 38 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 42 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2011 | 28 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 25 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2011 | 58 | 0.020 |
Why?
|
| Autonomic Nerve Block | 1 | 2011 | 10 | 0.020 |
Why?
|
| Analgesia | 1 | 2011 | 30 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 783 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 289 | 0.020 |
Why?
|
| Social Support | 1 | 2011 | 183 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2012 | 494 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2010 | 3 | 0.020 |
Why?
|
| Half-Life | 1 | 2010 | 22 | 0.020 |
Why?
|
| Biliary Tract | 1 | 2010 | 7 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2011 | 356 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 154 | 0.020 |
Why?
|
| Linear Models | 1 | 2009 | 445 | 0.020 |
Why?
|
| Sample Size | 1 | 2008 | 39 | 0.020 |
Why?
|
| United States | 2 | 2007 | 4108 | 0.020 |
Why?
|
| Muscle Neoplasms | 1 | 2007 | 8 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2007 | 23 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2007 | 69 | 0.020 |
Why?
|
| Antiemetics | 1 | 2007 | 6 | 0.020 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2006 | 4 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 116 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2008 | 876 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2007 | 128 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 682 | 0.010 |
Why?
|
| Farnesyltranstransferase | 1 | 2004 | 2 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2004 | 31 | 0.010 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2004 | 23 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 59 | 0.010 |
Why?
|
| Flavonoids | 1 | 2004 | 19 | 0.010 |
Why?
|
| Peritoneal Neoplasms | 1 | 2007 | 263 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2004 | 82 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 881 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2007 | 1844 | 0.010 |
Why?
|
| Vinblastine | 1 | 2000 | 3 | 0.010 |
Why?
|
| Remission Induction | 1 | 2000 | 86 | 0.010 |
Why?
|
| Child | 1 | 2007 | 2478 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 160 | 0.010 |
Why?
|